key: cord-0992446-ne2d1vpl authors: Anker, Markus S.; Tschöpe, Carsten title: Reply to ‘Heart failure with preserved ejection fraction and COVID‐19: which comes first, the chicken or the egg?’ date: 2021-07-28 journal: Eur J Heart Fail DOI: 10.1002/ejhf.2305 sha: 1857a98c00b09193815e0bccfb353cebae14c479 doc_id: 992446 cord_uid: ne2d1vpl nan We thank Baratto et al. for their interesting and thought-provoking letter. Since SARS-CoV-2 particles have been found in cardiac tissue accompanied by tissue inflammation, 1 understanding the relation between COVID-19 and cardiac dysfunction is of utmost importance. This has spiked research in the past year in many different directions. [2] [3] [4] [5] While both cohorts from Caravita et al. 6 and Hadzibegovic et al. 7 suffered from COVID-19 disease, their major difference was that the patients from Caravita et al. 6 were all treated in an intensive care unit with mechanical ventilation, while the patients from Hadzibegovic et al. 7 were patients from a regular ward without any additional circulatory or respiratory support -making them somewhat complicated to compare. Especially those patients in the intensive care unit have a variety of possible causes for left ventricular (LV) systolic and diastolic dysfunction or changes in pulmonary pressure despite possible viral-directed mechanisms. These include indirect damage through cytokine storm and the interaction of many factors such as continuous mechanical airway ventilation with possible lung compression and injury, decompensation, volume overload, and catecholamine treatment. 8 Studies with long-term cardiovascular follow-ups of COVID-19 patients are needed to better understand whether cardiovascular problems seen in the acute phase of COVID-19 patients also persist in the remission phase. Especially, whether diastolic dysfunction, that is seen in the acute phase of COVID-19 infection, will also persist in remission is important to investigate, because those patients would be at increased risk for developing heart failure with preserved ejection fraction (HFpEF) in the so- the HFA-PEFF 9 and H 2 FPEF 10 scores were not developed for unstable patients cared for in an intensive care setting. Here the reasons for changes in LV diastolic and right ventricular function, as well as changes in pulmonary pressure are very variable, multifactorial and do not represent the classical HFpEF syndrome. The scores estimate the likelihood for the classical diagnosis of HFpEF and a HFpEF-like syndrome, respectively, under stable conditions. In this context, HFpEF-like syndromes include a bundle of different cardiac aetiologies, including genetic and storage diseases as well as e.g. several myocardial inflammatory diseases, including viral myocarditis. We could show in our study for the first time that these scores are able to detect a HFpEF-like phenotype under COVID-19 conditions. It is of great interest to further assess these patients in their long-term follow-up to identify their risk of developing chronic HFpEF and to evaluate whether the HFA-PEFF and H 2 FPEF scores are sufficient for monitoring these patients. This is important since it is known that a subgroup of patients after viral or lymphocytic myocarditis can develop a HFpEF syndrome. 11 Additionally, COVID-19 patients in remission frequently report fatigue, tiredness, dyspnoea, and dizziness which has been termed 'long COVID' 12 -symptoms that are also frequently seen in HFpEF. [13] [14] [15] Myocardial localization of coronavirus in COVID-19 cardiogenic shock Impact of COVID-19 on inpatient referral of acute heart failure: a single-centre experience from the south-west of the UK Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications Cardiovascular implications of the COVID-19 pandemic: a global perspective Worsening of heart failure by coronavirus disease 2019 is associated with high mortality Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization SARS-CoV-2 related myocarditis like syndromes: Shakespeare's question: what's in a name? How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis Attributes and predictors of long COVID Impact of sex differences in co-morbidities and medication adherence on outcome in 25 776 heart failure patients Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations Signs and symptoms of heart failure: are you asking the right questions? Open Access funding enabled and organized by Projekt DEAL.